Eden Research has published its results for the six-months to June 2021. Revenues for the period were £0.79m (H1/20A £0.60m) and the operating loss was £1.75m (H1/20A £1.00m). Cash at the end of the period was £5.75m. As highlighted by recent announcements, the company sees a pick-up in regulatory approvals and anticipates US EPA approval of its Mevalone and Cedroz products in time for the 2022 growing season. We note Eden is continuing to progress its collaboration with Corteva and development ....
28 Sep 2021
Cenkos: Eden Research Plc -- Interim results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: Eden Research Plc -- Interim results
Eden Research plc (EDEN:LON) | 4.8 0 0.0% | Mkt Cap: 25.9m
- Published:
28 Sep 2021 -
Author:
Chris Donnellan -
Pages:
6
Eden Research has published its results for the six-months to June 2021. Revenues for the period were £0.79m (H1/20A £0.60m) and the operating loss was £1.75m (H1/20A £1.00m). Cash at the end of the period was £5.75m. As highlighted by recent announcements, the company sees a pick-up in regulatory approvals and anticipates US EPA approval of its Mevalone and Cedroz products in time for the 2022 growing season. We note Eden is continuing to progress its collaboration with Corteva and development ....